Xiangrui Meng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiangrui Meng has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Jianyuan Tang
TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
4 shared publications Hang Xiao
College of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China
3 shared publicationsLi Ma
College of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China
2 shared publications- Songtao Li
Traditional Chinese Medicine (TCM) Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 611137, PR China; Clinical School of Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, PR China
2 shared publications Bo Peng
Clinical School of Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, PR China
1 shared publicationChenyang Zhang
Beijing Key Laboratory of Diabetes Research and Care, Department of Endocrinology, Beijing Diabetes Institute, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 26 January 2026
- Published by Springer Nature in Chinese Medicine
- Vol. 21 (1) , 55
Molecular mechanism of berberine in ameliorating leptin resistance and mitochondrial dysfunction through the TRIB1-C/EBPα axis in obesity
Hyperleptinemia and mitochondrial dysfunction in obesity form a vicious cycle, underscoring the need for targeted interventions. This study suggests that berberine reduces leptin synthesis and improves leptin resistance by upregulating adipose tissue pseudokinase TRIB1 expression, promoting COP1-mediated C/EBPα ubiquitination and degradation, enhancing STAT3 phosphorylation, and suppressing SOCS3 expression. Meanwhile, TRIB1 appears to mediate the remodeling of mitochondrial dynamics by increasing the expression of fusion proteins MFN1 and L-OPA1, inhibiting the activity of the fission protein DRP1, reversing mitochondrial fragmentation, improving respiratory metabolic capacity, and thereby enhancing brown adipose tissue (BAT) thermogenesis. In TRIB1 knockout mice, the dual effects of berberine—central reduction of high-fat diet intake and peripheral promotion of lipolysis and thermogenesis—were largely abolished. Collectively, these findings support a model in which TRIB1 serves as a critical mediator through which berberine coordinates leptin signaling and mitochondrial function, providing mechanistic insight that may inform future strategies for obesity intervention. Graphical Abstract
- 26 January 2026
- Published by Springer Nature in Chinese Medicine
- Vol. 21 (1) , 55
Open AccessMolecular mechanism of berberine in ameliorating leptin resistance and mitochondrial dysfunction through the TRIB1-C/EBPα axis in obesity
Hyperleptinemia and mitochondrial dysfunction in obesity form a vicious cycle, underscoring the need for targeted interventions. This study suggests that berberine reduces leptin synthesis and improves leptin resistance by upregulating adipose tissue pseudokinase TRIB1 expression, promoting COP1-mediated C/EBPα ubiquitination and degradation, enhancing STAT3 phosphorylation, and suppressing SOCS3 expression. Meanwhile, TRIB1 appears to mediate the remodeling of mitochondrial dynamics by increasing the expression of fusion proteins MFN1 and L-OPA1, inhibiting the activity of the fission protein DRP1, reversing mitochondrial fragmentation, improving respiratory metabolic capacity, and thereby enhancing brown adipose tissue (BAT) thermogenesis. In TRIB1 knockout mice, the dual effects of berberine—central reduction of high-fat diet intake and peripheral promotion of lipolysis and thermogenesis—were largely abolished. Collectively, these findings support a model in which TRIB1 serves as a critical mediator through which berberine coordinates leptin signaling and mitochondrial function, providing mechanistic insight that may inform future strategies for obesity intervention. Graphical Abstract
- 29 December 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 390, 114581
Natural killer cell nano-engagers drive ferroptosis–immunomodulation synergy via inhibition of the Interleukin-6-JAK2-STAT3 Axis
- 29 December 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 390, 114581
Natural killer cell nano-engagers drive ferroptosis–immunomodulation synergy via inhibition of the Interleukin-6-JAK2-STAT3 Axis
- Open Access
- 17 June 2024
- Published by Elsevier in Biomaterials
- Vol. 311, 122670
Combined drug anti-deep vein thrombosis therapy based on platelet membrane biomimetic targeting nanotechnology
- 17 June 2024
- Published by Elsevier in Biomaterials
- Vol. 311, 122670
Open AccessCombined drug anti-deep vein thrombosis therapy based on platelet membrane biomimetic targeting nanotechnology
- Open Access
- 1 January 2024
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 15 (8) , 2361-2372
Evodiamine Inhibits Colorectal Cancer Growth via RTKs Mediated PI3K/AKT/p53 Signaling Pathway
Objective: To investigate the inhibitory effect of EVO on colorectal cancer (CRC) growth and further explore the potential mechanism involving the RTKs-mediated PI3K/AKT/p53 signaling pathway.
- 1 January 2024
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 15 (8) , 2361-2372
Open AccessEvodiamine Inhibits Colorectal Cancer Growth via RTKs Mediated PI3K/AKT/p53 Signaling Pathway
Objective: To investigate the inhibitory effect of EVO on colorectal cancer (CRC) growth and further explore the potential mechanism involving the RTKs-mediated PI3K/AKT/p53 signaling pathway.
- 25 November 2023
- Published by Elsevier in Acta Biomaterialia
- Vol. 174, 26-48
Cell membrane-based biomimetic technology for cancer phototherapy: Mechanisms, recent advances and perspectives
- 25 November 2023
- Published by Elsevier in Acta Biomaterialia
- Vol. 174, 26-48
Cell membrane-based biomimetic technology for cancer phototherapy: Mechanisms, recent advances and perspectives